ea0089c1 | Clinical – Chemo/SSA/Biologics | NANETS2022
Singh Simron
, Buikhuisen Wieneke
, Capdevila Jaume
, Caplin Martyn E
, Grohe Christian
, Horsch Dieter
, Raderer Markus
, Reidy-Lagunes Diane
, Wolin Edward M
, Pommie Christelle
, Mai Truong Xuan
, Baudin Eric
Background: SPINET was a phase 3 trial (NCT02683941) in patients with well-differentiated, advanced bronchopulmonary neuroendocrine tumors (NETs; typical and atypical carcinoids [TCs and ACs]). During the double-blind (DB) period, patients were randomized (2:1) to receive lanreotide autogel/depot (LAN; 120 mg) or placebo (PBO) every 28 days; in the optional open-label (OL) phase, all patients received LAN. Recruitment was stopped early due to slow accrual; all eligible patient...